| Market Cap | 4.05M | P/E | - | EPS this Y | 48.30% | Ern Qtrly Grth | - |
| Income | -7.79M | Forward P/E | -0.45 | EPS next Y | 52.20% | 50D Avg Chg | -24.00% |
| Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -69.00% |
| Dividend | N/A | Price/Book | 0.37 | EPS next 5Y | - | 52W High Chg | -90.00% |
| Recommedations | 2.00 | Quick Ratio | 4.59 | Shares Outstanding | 6.66M | 52W Low Chg | 30.00% |
| Insider Own | 3.85% | ROA | -67.36% | Shares Float | 5.99M | Beta | 0.87 |
| Inst Own | 6.19% | ROE | -125.96% | Shares Shorted/Prior | 77.57K/71.36K | Price | 1.27 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 898,738 | Target Price | 1.50 |
| Oper. Margin | - | Earnings Date | May 16 | Volume | 57,364 | Change | 0.00% |
Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of anxillary hyperhidrosis and aesthetic conditions. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
| Maxim Group | Buy | Mar 23, 23 |